摘要
Chronic hepatitis B(CHB)affects approximately 257 million individuals worldwide,the highest prevalence being in Western Pacific WHO Region[6.2%(1)].In highly endemic CHB regions,the 5-year cumulative incidence of hepatocellular carcinoma(HCC)ranges from 3%to 17%,depending on the presence of cirrhosis(2).Antiviral treatment decreases the risk of HCC,without abolishing it completely(3).Paradoxically,by decreasing liver-related mortality,antiviral treatment in CHB patients causes an increase in HCC long-term incidence(4).
